Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis

Journal of Clinical Investigation

Volumn 127, Issue 8, 2017, Pages 2998-3012

  Zang, Shengbing ^a,b   Li, Jia ^a,b   Yang, Haiyan ^c   Zeng, Hongxiang ^a,b   Han, Wei ^a,b   Zhang, Jixiang ^a,b,d   Lee, Minjung ^a,b   Moczygemba, Margie ^a   Isgandarova, Sevinj ^a   Yang, Yaling ^e   Zhou, Yubin ^a,b   Rao, Anjana ^f,g,h   You, M James ^e,i   Sun, Deqiang ^a,b,j   Huang, Yun ^a,b,j  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^g SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLCYTOSINE; CASPASE 3; CD4 ANTIGEN; CD8 ANTIGEN; CYCLIN D1; GUANOSINE TRIPHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; DNA BINDING PROTEIN; ONCOPROTEIN; OXIDOREDUCTASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; RHOA PROTEIN, MOUSE; TET2 PROTEIN, HUMAN; TET2 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL DISRUPTION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LOSS OF FUNCTION MUTATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; OVERLAPPING GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; ANIMAL; CELL CYCLE; CYTOLOGY; DNA METHYLATION; FEMALE; GENETIC EPIGENESIS; GENETICS; HOMEOSTASIS; IMMUNOLOGY; MALE; METABOLISM; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

5-METHYLCYTOSINE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CELL PROLIFERATION; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GTP PHOSPHOHYDROLASES; HOMEOSTASIS; HUMANS; MALE; MICE; MUTATION; OXIDOREDUCTASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 85026675493     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI92026     Document Type: Article

References (56)

1. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756-6767.
2. Bajor-Dattilo EB, Pittaluga S, Jaffe ES. Pathobiology of T-cell and NK-cell lymphomas. Best Pract Res Clin Haematol. 2013;26(1):75-87.
3. Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25-34.
4. Cortés JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol. 2016;23(4):434-443.
5. Weinstock DM, et al. A roadmap for discovery and translation in lymphoma. Blood. 2015;125(13):2175-2177.
6. Sakata-Yanagimoto M, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171-175.
7. Palomero T, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166-170.
8. Yoo HY, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371-375.
9. Odejide O, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293-1296.
10. Cortes JR, Ferrando A, Palomero T. Molecular pathogenesis of malignant lymphomas: PTCL, NOS AITL. In: Lenz G, Pasqualucci L, eds. Malignant Lymphomas: Biology and Molecular Pathogenesis. Berlin, Germany: De Gruyter; 2016;16:311-22.
11. Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol. 2013;26 Suppl 1:S71-S87.
12. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935.
13. Koh KP, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell. 2011;8(2):200-213.
14. He YF, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;333(6047):1303-1307.
15. Ito S, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333(6047):1300-1303.
16. Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843.
17. Bejar R, et al. Validation of a prognostic model and the impact of mutations in patients with lowerrisk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376-3382.
18. Delhommeau F, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
19. Tefferi A, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009;23(7):1343-1345.
20. Quivoron C, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25-38.
21. Lemonnier F, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFHlike features and adverse clinical parameters. Blood. 2012;120(7):1466-1469.
22. Abdel-Wahab O, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147.
23. Busque L, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181.
24. Moran-Crusio K, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24.
25. Ko M, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA. 2011;108(35):14566-14571.
26. Li Z, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17):4509-4518.
27. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111(7):2548-2553.
28. Vojtek AB, Cooper JA. Rho family members: activators of MAP kinase cascades. Cell. 1995;82(4):527-529.
29. Cleverley SC, Costello PS, Henning SW, Cantrell DA. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene. 2000;19(1):13-20.
30. Tybulewicz VL, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol. 2009;9(9):630-644.
31. Nagata Y, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood. 2016;127(5):596-604.
32. Sheikha A, Aljanadi M, Alshehri M, Raziuddin S. Peripheral T-cell lymphomas - cytokine profile and characteristic interleukin-4 and tumornecrosis-factor alpha-deficiency. Int J Oncol. 1994;4(1):91-95.
33. Muto H, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4:e264.
34. Waring P, Müllbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol. 1999;77(4):312-317.
35. Ichiyama K, et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity. 2015;42(4):613-626.
36. Nurieva R, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448(7152):480-483.
37. Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev. 2011;241(1):260-268.
38. Yue X, et al. Control of Foxp3 stability through modulation of TET activity. J Exp Med. 2016;213(3):377-397.
39. Yang R, et al. Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis. Immunity. 2015;43(2):251-263.
40. Sasidharan Nair V, Song MH, Oh KI. Vitamin C Facilitates Demethylation of the Foxp3 Enhancer in a Tet-Dependent Manner. J Immunol. 2016;196(5):2119-2131.
41. Chen W, Konkel JE. TGF-beta and 'adaptive' Foxp3(+) regulatory T cells. J Mol Cell Biol. 2010;2(1):30-36.
42. de Leval L, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952-4963.
43. Piccaluga PP, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007;67(22):10703-10710.
44. Kataoka K, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.
45. Ouyang W, Beckett O, Flavell RA, Li MO. An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity. 2009;30(3):358-371.
46. Kerdiles YM, et al. Foxo transcription factors control regulatory T cell development and function. Immunity. 2010;33(6):890-904.
47. Ouyang W, Li MO. Foxo: in command of T lymphocyte homeostasis and tolerance. Trends Immunol. 2011;32(1):26-33.
48. Du X, et al. Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease. J. Immunol. 2014;192(4):1525-1535.
49. Shih AH, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27(4):502-515.
50. Zhang X, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48(9):1014-1023.
51. Scourzic L, et al. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia. 2016;30(6):1388-1398.
52. Cutucache CE, Herek TA. Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS. Front Oncol. 2016;6:206.
53. Hedrick SM, Hess Michelini R, Doedens AL, Goldrath AW, Stone EL. FOXO transcription factors throughout T cell biology. Nat Rev Immunol. 2012;12(9):649-661.
54. Lainé A, et al. Foxo1 Is a T Cell-Intrinsic Inhibitor of the RORγt-Th17 Program. J Immunol. 2015;195(4):1791-1803.
55. Stone EL, et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity. 2015;42(2):239-251.
56. Sun D, et al. MOABS: model based analysis of bisulfite sequencing data. Genome Biol. 2014;15(2):R38